Clinical Trials Logo

Clinical Trial Summary

Hand foot skin reaction (HFS) from capecitabine is one of the most common adverse events from capecitabine. Urea cream has been proved its benefit to prevent HFS from sorafenib. Prior study using urea cream prophylaxis in patients receiving capecitabine was negative. However, result from aformentioned study was reported primarily from result of first cycle capecitabine. Urea cream as a prevention of HFS from capecitabine has been used in clinical practice in Thailand according to expert's opinion. We conducted the study to evaluate wheter the urea cream can prevent HFS or severe HFS.


Clinical Trial Description

The patients who is planned to receive capecitabine for at least 3 cycles were enrolled in the study. The patients were randomized to receive 10% urea cream or standard measure. The patients were followed until the end of capecitabine treatment. The patients reported their symptoms of HFS and other adverse events (AE) before starting new cycle of capecitabine. Physician record of HFS and other AE, dose modification of capecitabine and compliance were extracted. We will report incidence of any HFS, > grade 3 HFS, capecitabine interruption or delay or discontinuation and time to develop HFS among both arms. The results of the study will be used for optimal prophylactic measures in patients treated with capecitabine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05348278
Study type Interventional
Source Mahidol University
Contact Suthinee Ithimakin, MD
Phone +6624194489
Email aesi105@yahoo.co.th
Status Recruiting
Phase Phase 2/Phase 3
Start date December 20, 2021
Completion date August 2023

See also
  Status Clinical Trial Phase
Completed NCT04592731 - Acetylated Natural Nucleotides in Treating Hand-foot Syndrome N/A
Completed NCT05755646 - Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial N/A
Completed NCT00446147 - Study of Pyridoxine for Hand-Foot Syndrome Phase 3
Completed NCT01609166 - Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome Phase 2
Terminated NCT03173365 - The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients Phase 2
Recruiting NCT04979078 - Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction N/A
Recruiting NCT05165069 - The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome Phase 3
Recruiting NCT04833998 - Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine Phase 2
Not yet recruiting NCT05949307 - The Efficacy of Acupuncture and Laser Acupuncture in Treating Chemotherapy or Target Therapy-induced Hand-foot Syndrome N/A